Influenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia;
Influenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Pediatrics. 2019 Feb;143(2). doi: 10.1542/peds.2018-2094. Epub 2019 Jan 7.
Researchers in observational studies of vaccine effectiveness (VE) in which they compared quadrivalent live attenuated vaccine (LAIV4) and inactivated influenza vaccine (IIV) among children and adolescents have shown inconsistent results, and the studies have been limited by small samples.
We combined data from 5 US studies from 2013-2014 through 2015-2016 to compare the VE of LAIV4 and IIV against medically attended, laboratory-confirmed influenza among patients aged 2 to 17 years by influenza season, subtype, age group, and prior vaccination status. The VE of IIV or LAIV4 was calculated as 100% × (1 - odds ratio), comparing the odds of vaccination among patients who were influenza-positive to patients who were influenza-negative from adjusted logistic regression models. Relative effectiveness was defined as the odds of influenza comparingLAIV4 and IIV recipients.
Of 17 173 patients aged 2 to 17 years, 4579 received IIV, 1979 received LAIV4, and 10 615 were unvaccinated. Against influenza A/H1N1pdm09, VE was 67% (95% confidence interval [CI]: 62% to 72%) for IIV and 20% (95% CI: -6% to 39%) for LAIV4. Results were similar when stratified by vaccination in the previous season. LAIV4 recipients had significantly higher odds of influenza A/H1N1pdm09 compared with IIV recipients (odds ratio 2.66; 95% CI: 2.06 to 3.44). LAIV4 and IIV had similar effectiveness against influenza A/H3N2 and B. Our overall findings were consistent when stratified by influenza season and age group.
From this pooled individual patient-level data analysis, we found reduced effectiveness of LAIV4 against influenza A/H1N1pdm09 compared with IIV, which is consistent with published results from the individual studies included.
在观察性研究中,研究人员比较了四价活减毒疫苗(LAIV4)和流感灭活疫苗(IIV)在儿童和青少年中的疫苗有效性(VE),结果不一致,且这些研究受到样本量小的限制。
我们结合了 2013-2014 年至 2015-2016 年期间来自美国的 5 项研究的数据,通过流感季节、亚型、年龄组和既往接种状态,比较了每剂 LAIV4 和 IIV 对 2 至 17 岁患者因流感就诊、经实验室确诊的流感的 VE。通过调整后的 logistic 回归模型,比较接种患者与未接种患者的流感阳性率,计算 IIV 或 LAIV4 的 VE。相对有效性定义为 LAIV4 和 IIV 接受者的流感发生率之比。
在 17173 名 2 至 17 岁的患者中,4579 人接受了 IIV,1979 人接受了 LAIV4,10615 人未接种疫苗。对于甲型 H1N1pdm09 流感,IIV 的 VE 为 67%(95%可信区间[CI]:62%至 72%),LAIV4 的 VE 为 20%(95% CI:-6%至 39%)。按上一季接种情况分层时,结果相似。与 IIV 接受者相比,LAIV4 接受者感染甲型 H1N1pdm09 的几率明显更高(比值比 2.66;95% CI:2.06 至 3.44)。LAIV4 和 IIV 对甲型 H3N2 和乙型流感的有效性相似。我们的总体发现与纳入的个体研究的结果一致。
从这项汇总的个体患者水平数据分析中,我们发现与 IIV 相比,LAIV4 对甲型 H1N1pdm09 的有效性降低,这与已发表的个别研究结果一致。